MARKET

ADMP

ADMP

Adamis Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4610
+0.0142
+3.18%
After Hours: 0.4610 0 0.00% 19:27 05/27 EDT
OPEN
0.4600
PREV CLOSE
0.4468
HIGH
0.4747
LOW
0.4468
VOLUME
532.70K
TURNOVER
0
52 WEEK HIGH
1.480
52 WEEK LOW
0.3118
MARKET CAP
69.03M
P/E (TTM)
-2.2924
1D
5D
1M
3M
1Y
5Y
Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
It’s been a long and arduous road for Revive Therapeutics Ltd. (OTC: RVVTF) regarding their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.
Benzinga · 05/19 15:49
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/19 12:01
BRIEF-Adamis Pharmaceuticals Announces Leadership Transition To Support New Phase Of Innovation And Growth
reuters.com · 05/18 22:10
Adamis Pharmaceuticals names co-founder David Marguglio as CEO
Adamis Pharmaceuticals (NASDAQ:ADMP) on Wednesday said it had appointed co-founder and chief business officer David Marguglio as its new president and CEO. Marguglio replaces Dennis Carlo, who has also stepped
Seekingalpha · 05/18 21:14
Adamis Pharmaceuticals Appoints Chief Business Officer David Marguglio as CEO
MT Newswires · 05/18 17:24
Adamis Pharma stock falls 9% despite better-than expected Q1 revenue
Adamis Pharma (NASDAQ:ADMP -9.4%) posted better-than expected Q1 revenue on Monday after markets closed. Quarterly revenue fell 14% Y/Y to $1.2M, but beat analysts estimate by $1.1M. Revenues consisted mostly of about  $1.1M of
Seekingalpha · 05/17 15:01
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/17 12:09
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
More
No Data
Learn about the latest financial forecast of ADMP. Analyze the recent business situations of Adamis Pharmaceuticals Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADMP stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
High1.000
Average1.000
Low1.000
Current 0.4610
EPS
Actual
Estimate
-0.15-0.11-0.08-0.04
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2018
Institutional Holdings
Institutions: 76
Institutional Holdings: 15.44M
% Owned: 10.31%
Shares Outstanding: 149.73M
TypeInstitutionsShares
Increased
7
274.72K
New
4
90.76K
Decreased
13
1.08M
Sold Out
7
539.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Richard Williams
President/Chief Executive Officer/Director
David Marguglio
Chief Financial Officer/Chief Accounting Officer
David Benedicto
Other
Ronald Moss
Director
Meera Desai
Independent Director
Howard Birndorf
Independent Director
Vickie Reed
No Data
No Data
About ADMP
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. It is focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its product includes, SYMJEP (epinephrine) Injection 0.3 miligram for treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more, and SYMJEPI (epinephrine) Injection 0.15 miligram for the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates includes ZIMHI, a high dose 5 miligram naloxone injection, based on the approved Symject injection device for the treatment of opioid overdose, and APC-400 (tempol) for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19, APC-1000 a hydrofluoroalkane (HFA) inhalable oral steroid for the treatment of asthma and COPD APC-4000 Fluticasone, a dry powder inhalation for the treatment of asthma.

Webull offers kinds of Adamis Pharmaceuticals Corp stock information, including NASDAQ:ADMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMP stock methods without spending real money on the virtual paper trading platform.